Research Article
Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
Table 2
The proportions of improved response stratified by CNV type at 1 month after switching.
| | | Type 1 CNV | Type 2 CNV | PCV | Mixed CNV | value |
| | CMT | n = 21 | n = 5 | n = 25 | n = 13 | | | Improved, n (%) | 9 (42.9%) | 3 (60.0%) | 16 (64.0%) | 8 (61.5%) | 0.439 | | Unimproved, n (%) | 12 (57.1%) | 2 (40.0%) | 9 (36.0%) | 5 (38.5%) | |
| | mPEDH | n = 18 | n = 4 | n = 24 | n = 13 | | | Improved, n (%) | 13 (72.2%) | 3 (75.0%) | 17 (70.8%) | 7 (53.8%) | 0.780 | | Unimproved, n (%) | 5 (27.8%) | 1 (25.0%) | 7 (29.2%) | 6 (46.2%) | |
| | cPEDH | n = 10 | n = 3 | n = 19 | n = 7 | | | Improved, n (%) | 6 (60.0%) | 1 (33.3%) | 11 (57.9%) | 3 (42.9%) | 0.751 | | Unimproved, n (%) | 4 (40.0%) | 2 (66.7%) | 8 (42.1%) | 4 (57.1%) | |
| | IRF | n = 21 | n = 5 | n = 25 | n = 13 | | | Improved, n (%) | 1 (4.8%) | 1 (20%) | 5 (20%) | 1 (7.7%) | 0.245 | | Unimproved, n (%) | 20 (95.2%) | 4 (80%) | 20 (80%) | 12 (92.3%) | |
| | SRF | n = 21 | n = 5 | n = 25 | n = 13 | | | Improved, n (%) | 3 (14.3%) | 0 (0%) | 4 (16%) | 1 (7.7%) | 0.701 | | Unimproved, n (%) | 18 (85.7%) | 5 (100%) | 21 (84%) | 12 (92.3%) | |
| | BCVA | n = 21 | n = 5 | n = 25 | n = 13 | | | Improved, n (%) | 9 (42.9%) | 0 (0%) | 12 (48%) | 6 (46.2%) | 0.604 | | Unimproved, n (%) | 12 (57.1%) | 5 (100%) | 13 (52%) | 7 (53.8%) | |
|
|
CMT, central macular thickness; mPEDH, maximum PED height; cPEDH, PED height at foveal center; PED, pigmented epithelial detachment; IRF, intraretinal fluid; SRF, subretinal fluid; BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; PCV, polypoidal choroidal vasculopathy.
|
